The human deals with many diseases emerging from many sources, but only a few of them are curable. Diseases caused by viruses as sources are the most difficult ones to deal with. HTLV-1(Human T cell lymphotropic/leukaemia type-1) comes under retrovirus classification.In most cases, no sure cure is present till nowadays. The current status the estimated at 5 million to 10 million. The causative agents of both adult T cell leukaemia (ATL) and HTLV-1 Associated Myelopathy Spastic Paraparesis (HAM/TSP). The main geographical regions are the Southwestern part of Japan, Sub-Saharan Africa and South America. The initial stage of infection is unknown but certain studies show that the virus attack CD4+ T cells, CD34+, B lymphocytes, T lymphocytes and hematopoietic progenitor cells etc. Through an In-silicon approach for designing the drug against this protein expressed by HTLV-1 cells using bioinformatics database and software. Designing of ligands for substrate (HTLV-1) was performed.It was identified that the drug Allopathy Glatiramer, Plant-based drug Oleandrin and antibodies Doxycycline showed partially able to cure the T cell leukaemia virus replication protein structure.
Article Details
Unique Paper ID: 157287
Publication Volume & Issue: Volume 9, Issue 6
Page(s): 388 - 398
Article Preview & Download
Share This Article
Conference Alert
NCSST-2021
AICTE Sponsored National Conference on Smart Systems and Technologies
Last Date: 25th November 2021
SWEC- Management
LATEST INNOVATION’S AND FUTURE TRENDS IN MANAGEMENT